There is evidence indicating ROS1, RET fusion, and MET exon 14 mutations could associate with an inadequate response to ICIs despite high PD-L1 expression [32], and several specific gene alterations could also affect the efficacy of ICIs in NSCLC (e.g., KEAP1, STK11, and KRAS) [33]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.